MXPA04005880A - Cis-imidazolinas como inhibidores de la mdm2. - Google Patents

Cis-imidazolinas como inhibidores de la mdm2.

Info

Publication number
MXPA04005880A
MXPA04005880A MXPA04005880A MXPA04005880A MXPA04005880A MX PA04005880 A MXPA04005880 A MX PA04005880A MX PA04005880 A MXPA04005880 A MX PA04005880A MX PA04005880 A MXPA04005880 A MX PA04005880A MX PA04005880 A MXPA04005880 A MX PA04005880A
Authority
MX
Mexico
Prior art keywords
imidazolines
cis
mdm2 inhibitors
formula
mdm2
Prior art date
Application number
MXPA04005880A
Other languages
English (en)
Inventor
Thanh Vu Binh
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04005880A publication Critical patent/MXPA04005880A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona compuestos de acuerdo con la formula I y de la formula II(ver formula I, II)y sales y esteres farmaceuticamente aceptables de los mismos, que tienen las designaciones proporcionadas en la presente y que inhiben la interaccion de la proteina MDM2 con un peptido similar a p53 y que presentan una actividad antiproliferativa.
MXPA04005880A 2001-12-18 2002-12-09 Cis-imidazolinas como inhibidores de la mdm2. MXPA04005880A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34172901P 2001-12-18 2001-12-18
US39087602P 2002-06-21 2002-06-21
PCT/EP2002/013905 WO2003051360A1 (en) 2001-12-18 2002-12-09 Cis-imidazolines as mdm2 inhibitors

Publications (1)

Publication Number Publication Date
MXPA04005880A true MXPA04005880A (es) 2004-09-13

Family

ID=26992633

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005880A MXPA04005880A (es) 2001-12-18 2002-12-09 Cis-imidazolinas como inhibidores de la mdm2.

Country Status (20)

Country Link
US (1) US6617346B1 (es)
EP (1) EP1463501B1 (es)
JP (1) JP4361798B2 (es)
KR (1) KR100640707B1 (es)
CN (1) CN1604778A (es)
AR (1) AR037882A1 (es)
AT (1) ATE397925T1 (es)
AU (1) AU2002361986B2 (es)
BR (1) BR0215156A (es)
CA (1) CA2468783A1 (es)
DE (1) DE60227108D1 (es)
ES (1) ES2307822T3 (es)
MX (1) MXPA04005880A (es)
PA (1) PA8561801A1 (es)
PE (1) PE20030717A1 (es)
PL (1) PL370909A1 (es)
RU (1) RU2312101C2 (es)
TW (1) TW200301696A (es)
UY (1) UY27586A1 (es)
WO (1) WO2003051360A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411597A (pt) * 2003-06-17 2006-08-29 Hoffmann La Roche cis-imidazolinas como inibidores de mdm2
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
KR20080027969A (ko) * 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
BRPI0511676A (pt) * 2004-05-29 2008-01-08 7Tm Pharma As uso medicinal de ligandos receptores
US7893278B2 (en) * 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
CA2598690C (en) * 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
KR101109437B1 (ko) 2005-12-01 2012-01-31 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린유도체
EP1979338A1 (en) * 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
US8614192B2 (en) 2006-07-28 2013-12-24 Leiden University Medical Center Method for treating ocular cancer
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
AU2007332493A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2009047161A1 (en) * 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
AU2010205201A1 (en) 2009-01-16 2011-08-04 Daiichi Sankyo Company,Limited Imidazothiazole derivative having proline ring structure
PE20121282A1 (es) 2009-11-12 2012-10-12 Univ Michigan Antagonistas de espiro-oxindol de mdm2
US10159669B2 (en) * 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
NZ611866A (en) 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists
KR101384683B1 (ko) * 2011-10-27 2014-04-11 한국생명공학연구원 ｍｄｍ２－결합 모티프를 포함하는 펩타이드 및 이의 용도
WO2013101436A1 (en) * 2011-12-07 2013-07-04 Duke University Methods of identifying and using mdm2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
BR112018070549A2 (pt) 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
EP3512831A4 (en) 2017-06-16 2019-07-31 Unity Biotechnology, Inc. SYNTHESIS PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY PURE CIS-IMIDAZOLINE COMPOUNDS FOR PHARMACEUTICAL USE
SG11202103282YA (en) 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
WO1992003421A2 (en) 1990-08-17 1992-03-05 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
GB2351082A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines

Also Published As

Publication number Publication date
RU2312101C2 (ru) 2007-12-10
PE20030717A1 (es) 2003-08-28
EP1463501B1 (en) 2008-06-11
BR0215156A (pt) 2004-10-19
TW200301696A (en) 2003-07-16
JP2005515210A (ja) 2005-05-26
AU2002361986A1 (en) 2003-06-30
KR100640707B1 (ko) 2006-10-31
DE60227108D1 (de) 2008-07-24
ATE397925T1 (de) 2008-07-15
RU2004122404A (ru) 2005-05-27
UY27586A1 (es) 2003-06-30
KR20040068289A (ko) 2004-07-30
EP1463501A1 (en) 2004-10-06
US6617346B1 (en) 2003-09-09
ES2307822T3 (es) 2008-12-01
AU2002361986B2 (en) 2008-04-10
AR037882A1 (es) 2004-12-09
JP4361798B2 (ja) 2009-11-11
CA2468783A1 (en) 2003-06-26
PA8561801A1 (es) 2003-07-28
WO2003051360A1 (en) 2003-06-26
PL370909A1 (en) 2005-05-30
CN1604778A (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
MXPA04005880A (es) Cis-imidazolinas como inhibidores de la mdm2.
PA8561901A1 (es) Cis-imidazolinas
TW200600501A (en) Novel cis-imidazolines
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
MX2009011019A (es) Difenil-dihidro-imidazopiridinonas.
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
IL143545A0 (en) Thrombin inhibitors
FI950309A0 (fi) Proliiniamidijohdannaisia
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
NZ533994A (en) Amino alcohol derivative or phosphonic acid derivative and medicinal compostion containing these
IL158485A (en) Spiropyrazole compounds
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
MXPA05013465A (es) Cis-imidazolinas como inhibidores de mdm2.
MXPA05013279A (es) Cis-2,4,5-triaril-imidazolinas.
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
DE69827614D1 (de) Chinoxalindionen
EP1303291A4 (en) ANTITUMOR AND ANTI-HIV PEPTIDES AND FRAGMENTS OF LYSOZYME
GB0206200D0 (en) Pharmaceutical compositions
EP1210948B8 (en) Therapeutic peptide for nervous diseases
DE69824410D1 (en) Antithrombosemittel
ECSP961755A (es) Agentes antifungicos de peptidos ciclicos (caso x-9249)
ECSP961756A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9250)
ECSP961754A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9539)

Legal Events

Date Code Title Description
FG Grant or registration